Jesper B. Andersen

16.7k total citations · 3 hit papers
113 papers, 5.8k citations indexed

About

Jesper B. Andersen is a scholar working on Surgery, Molecular Biology and Cancer Research. According to data from OpenAlex, Jesper B. Andersen has authored 113 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Surgery, 51 papers in Molecular Biology and 50 papers in Cancer Research. Recurrent topics in Jesper B. Andersen's work include Cholangiocarcinoma and Gallbladder Cancer Studies (45 papers), RNA modifications and cancer (24 papers) and Cancer-related molecular mechanisms research (18 papers). Jesper B. Andersen is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (45 papers), RNA modifications and cancer (24 papers) and Cancer-related molecular mechanisms research (18 papers). Jesper B. Andersen collaborates with scholars based in Denmark, United States and Germany. Jesper B. Andersen's co-authors include Snorri S. Thorgeirsson, Valentina M. Factor, Jens U. Marquardt, Marian E. Durkin, Monika Lewińska, Cédric Coulouarn, S S Thorgeirsson, Elizabeth A. Conner, Matthias S. Matter and Chiara Raggi and has published in prestigious journals such as Cell, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Jesper B. Andersen

108 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties

2009 601 citations Valentina M. Factor, Jesper B. Andersen et al. profile →
Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors

2011 384 citations Jesper B. Andersen, Elizabeth A. Conner et al. profile →
Lipid alterations in chronic liver disease and liver cancer

2022 202 citations Monika Lewińska, Jesper B. Andersen et al. JHEP Reports profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jesper B. Andersen Denmark	41	3.3k	2.4k	1.7k	1.5k	908	113	5.8k
Jesús M. Bañales Spain	41	2.4k 0.7×	1.3k 0.5×	2.4k 1.4×	1.3k 0.8×	1.5k 1.7×	169	6.0k
Jian Zhou China	39	2.5k 0.7×	1.8k 0.8×	1.0k 0.6×	2.0k 1.3×	1.8k 1.9×	225	6.6k
Jing‐Ping Yun China	41	3.5k 1.0×	2.5k 1.1×	614 0.4×	1.6k 1.1×	398 0.4×	151	5.8k
Qiongzhu Dong China	49	4.5k 1.4×	3.6k 1.5×	551 0.3×	1.8k 1.2×	701 0.8×	131	7.4k
Zhi Dai China	38	2.7k 0.8×	1.9k 0.8×	521 0.3×	1.7k 1.1×	677 0.7×	97	5.4k
Wolfgang Mikulits Austria	44	4.1k 1.2×	1.6k 0.7×	535 0.3×	2.4k 1.6×	955 1.1×	116	6.9k
Mengchao Wu China	37	1.9k 0.6×	958 0.4×	872 0.5×	1.1k 0.7×	1.0k 1.1×	120	4.5k
Stephanie Ma Hong Kong	47	5.0k 1.5×	3.0k 1.3×	795 0.5×	3.9k 2.6×	1.4k 1.6×	125	8.8k
Wei‐Fen Xie China	38	2.1k 0.6×	999 0.4×	859 0.5×	905 0.6×	1.2k 1.3×	116	4.3k
Won Sang Park South Korea	55	6.3k 1.9×	2.3k 1.0×	932 0.6×	2.6k 1.7×	458 0.5×	217	9.0k

Countries citing papers authored by Jesper B. Andersen

Since Specialization

Citations

This map shows the geographic impact of Jesper B. Andersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesper B. Andersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesper B. Andersen more than expected).

Fields of papers citing papers by Jesper B. Andersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesper B. Andersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesper B. Andersen. The network helps show where Jesper B. Andersen may publish in the future.

Co-authorship network of co-authors of Jesper B. Andersen

This figure shows the co-authorship network connecting the top 25 collaborators of Jesper B. Andersen. A scholar is included among the top collaborators of Jesper B. Andersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesper B. Andersen. Jesper B. Andersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schou, Jakob Vasehus, et al.. (2025). Personalized Neoadjuvant Chemotherapy for Gastrointestinal Cancers: Shaping Imprecision to be Precise. Clinical Cancer Research. 31(12). 2309–2316.

Singh, Yashbir, Jesper B. Andersen, Quincy A. Hathaway, et al.. (2025). Leveraging Multimodal Foundation Models in Biliary Tract Cancer Research. Tomography. 11(9). 96–96. 1 indexed citations

O’Rourke, Colm J., Jonathan Frederik Carlsen, Jonathan Cohen, et al.. (2025). Clinical, radiological, and molecular insights into extracranial metastases from adult gliomas. Neuro-Oncology. 28(1). 99–114.

Zhuravleva, Ekaterina, Monika Lewińska, Colm J. O’Rourke, et al.. (2024). Mutational signatures define immune and Wnt-associated subtypes of ampullary carcinoma. Gut. 74(5). 804–814. 1 indexed citations

Ashworth, J., Alison Ritchie, Nigel P. Mongan, et al.. (2024). The role of mesenchymal cells in cholangiocarcinoma. Disease Models & Mechanisms. 17(12). 2 indexed citations

Oliveira, Douglas V.N.P., Edyta Biskup, Colm J. O’Rourke, et al.. (2024). Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors. Molecular Diagnosis & Therapy. 28(6). 821–834. 1 indexed citations

Rodrigues, Pedro M., Marta B. Afonso, André L. Simão, et al.. (2023). miR‐21‐5p promotes NASH‐related hepatocarcinogenesis. Liver International. 43(10). 2256–2274. 22 indexed citations

Lewińska, Monika, et al.. (2023). Serum lipidome unravels a diagnostic potential in bile acid diarrhoea. Gut. 72(9). 1698–1708. 11 indexed citations

Lewińska, Monika, et al.. (2022). Lipid alterations in chronic liver disease and liver cancer. JHEP Reports. 4(6). 100479–100479. 202 indexed citations breakdown →

10.

Muñoz-Garrido, Patricia, Monika Lewińska, Letizia Satriano, et al.. (2022). MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells. Journal of Hepatology. 78(2). 364–375. 21 indexed citations

11.

Zimmer, Christine L., Iva Filipovic, Martin Cornillet, et al.. (2021). Mucosal‐associated invariant T‐cell tumor infiltration predicts long‐term survival in cholangiocarcinoma. Hepatology. 75(5). 1154–1168. 26 indexed citations

12.

O’Rourke, Colm J., Christian Dehlendorff, Ole Larsen, et al.. (2020). Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. Clinical Cancer Research. 26(21). 5655–5667. 21 indexed citations

13.

Nepal, Chirag, Yavor Hadzhiev, Piotr J. Balwierz, et al.. (2020). Dual-initiation promoters with intertwined canonical and TCT/TOP transcription start sites diversify transcript processing. Nature Communications. 11(1). 168–168. 29 indexed citations

14.

O’Rourke, Colm J., Patricia Muñoz-Garrido, & Jesper B. Andersen. (2020). Molecular Targets in Cholangiocarcinoma. Hepatology. 73(S1). 62–74. 31 indexed citations

15.

Maira, Giovanni Di, Alessandra Gentilini, Mirella Pastore, et al.. (2019). The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. Oncogenesis. 8(11). 61–61. 30 indexed citations

16.

Satriano, Letizia, Monika Lewińska, Pedro M. Rodrigues, Jesús M. Bañales, & Jesper B. Andersen. (2019). Metabolic rearrangements in primary liver cancers: cause and consequences. Nature Reviews Gastroenterology & Hepatology. 16(12). 748–766. 161 indexed citations

17.

Lee, Yun-Han, Daekwan Seo, Kyung‐Ju Choi, et al.. (2014). Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2. Cancer Research. 74(17). 4752–4761. 77 indexed citations

18.

Stauffer, Jimmy K., Anthony J. Scarzello, Jesper B. Andersen, et al.. (2011). Coactivation of AKT and β-Catenin in Mice Rapidly Induces Formation of Lipogenic Liver Tumors. Cancer Research. 71(7). 2718–2727. 68 indexed citations

19.

Lee, Yun-Han, Jesper B. Andersen, Ho‐Taek Song, et al.. (2010). Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma. Cancer Research. 70(21). 8264–8269. 60 indexed citations

20.

Feng, Qing, David Sekula, Yongli Guo, et al.. (2008). UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular Cancer Therapeutics. 7(12). 3780–3788. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact